Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ME On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeME23andMe$0.50-35.3%$1.68$0.53▼$12.76$13.36M1.191.18 million shs29.28 million shsElon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceME23andMe0.00%0.00%-67.02%-87.70%-94.88%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationME23andMe1.4153 of 5 stars2.81.00.00.02.81.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceME23andMe 1.50Reduce$9.401,787.55% UpsideCurrent Analyst Ratings BreakdownLatest ME Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/22/2025ME23andMeWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)3/7/2025ME23andMeWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)2/19/2025ME23andMeWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)2/1/2025ME23andMeWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)1/18/2025ME23andMeWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 4/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookME23andMe$208.78M0.06$0.54 per share0.93$2.34 per share0.21Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateME23andMe-$666.70M-$15.45N/A∞N/A-183.39%-170.07%-62.13%N/ALatest ME EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails1/28/2025Q3 2025ME23andMeN/A-$1.02N/A-$1.73N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthME23andMeN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioME23andMeN/A1.050.91Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipME23andMe36.10%Insider OwnershipCompanyInsider OwnershipME23andMe26.32%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableME23andMe77026.83 million19.77 millionNot OptionableME HeadlinesRecent News About These CompaniesAttorney general warns Kentuckians to protect DNA data amid 23andMe bankruptcyApril 9 at 2:55 PM | wdrb.comKentucky Attorney General urges people to delete 23andMe dataApril 9 at 2:55 PM | msn.comAttorney General Coleman issues data warning after 23andMe files bankruptcyApril 9 at 2:55 PM | lex18.comAG Coleman encourages Kentuckians to delete 23andMe dataApril 9 at 2:55 PM | msn.com23andMe probe launched to prevent customer DNA data from being sold to China or other bad actorsApril 9 at 10:16 AM | foxbusiness.comWashington state reminds 23andMe users: You can delete your DNA dataApril 9 at 2:33 AM | msn.com23andMe is bankrupt. What will happen to customer data and the future of DNA testing?April 6, 2025 | sbs.com.auIowa AG warns residents to protect their 23andMe data as company faces bankruptcyApril 5, 2025 | msn.comHow to delete genetic data from 23andMeApril 5, 2025 | seattleweekly.comAttorney General James urges 23AndMe customers to contact company to delete dataApril 5, 2025 | yahoo.comBig Take: 23andMe Bankruptcy Puts a Price on Your DNAApril 5, 2025 | bloomberg.com23andMe Bankruptcy Puts Spotlight on Genetic Privacy ComplianceApril 4, 2025 | news.bloomberglaw.comIowans warned their genetic data may be at risk in 23andMe bankruptcyApril 3, 2025 | kimt.comMichigan AG Dana Nessel Issues Alert on Privacy Risks of Genetic Testing Services Amid 23andMe BankruptcyApril 3, 2025 | hoodline.com23andMe bankruptcy raises concerns over fate of customer genetic dataApril 3, 2025 | wmar2news.comPa. officials seek DNA privacy following 23andMe bankruptcy | Today in Pa.April 3, 2025 | msn.comFTC: 23andMe buyer must honor firm’s privacy promises for genetic dataApril 3, 2025 | arstechnica.com23andMe Files for Chapter 11: What's Next for Your Data?April 3, 2025 | msn.com23andMe is potentially selling more than just genetic data. The personal survey info is also a privacy problem.April 3, 2025 | msn.comThese are the people who want to buy 23andMeApril 1, 2025 | msn.com23andMe has filed for bankruptcy. What does this mean for your DNA data privacy?March 25, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesNVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a BuyBy Thomas Hughes | March 12, 2025View NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a Buy3 Defense Stocks Set to Benefit From Increased Military SpendingBy Chris Markoch | March 20, 2025View 3 Defense Stocks Set to Benefit From Increased Military SpendingNVIDIA Stock Remains Stunningly Undervalued—Here’s WhyBy Thomas Hughes | March 11, 2025View NVIDIA Stock Remains Stunningly Undervalued—Here’s Why3 Stocks Near 52-Week Lows With Strong Rebound PotentialBy Gabriel Osorio-Mazilli | March 31, 2025View 3 Stocks Near 52-Week Lows With Strong Rebound PotentialNVIDIA Insiders Sell: This Is What It Means for the Market By Thomas Hughes | March 25, 2025View NVIDIA Insiders Sell: This Is What It Means for the Market ME Company Descriptions23andMe NASDAQ:ME$0.50 -0.27 (-35.32%) Closing price 03/28/2025Extended Trading$0.50 0.00 (0.00%) As of 03/28/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.23andMe Holding Co. operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. This segments also operates Lemonaid telehealth platform to access affiliated licensed healthcare professionals for medical consultation and treatment for various common conditions; and offers research services. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to enhance patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing intellectual property associated with identified drug targets related to drug candidates under clinical development. The company's therapeutics product portfolio comprises 23ME-00610 (P006), a humanized monoclonal antibody, which is in phase 1/2a clinical trials to interfere with the ability of CD200R1 to interact with CD200 in cancer cells; and GSK6097608, an antibody that targets CD96 for attenuating T and NK cell anti-tumor immune responses. The company was incorporated in 2006 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Is Alphabet a Generational Buying Opportunity at These Levels? Is Microsoft Stock Too Cheap to Ignore After Its Latest Drop? Harley-Davidson Tops Watchlists: Value Trap or Turnaround Play? Strategy’s $5 Million Bitcoin Target: Beacon or Bagholder? Amazon Stock Bounces From Lows as Smart Money Steps In Qualcomm Breaks Down But RSI Signals It’s Severely Oversold Tesla’s #1 Bull Cuts Target But Says It’s Still a Buy Will CrowdStrike's Goodwill Strategy Pay Off in Revenue Gains? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
